Mometasone市场：依剂型、适应症、给药途径、通路及地区划分。

2026年，糠酸Mometasone市场规模估计为15.826亿美元，预计2033年将达到26.08亿美元。预计2026年至2033年，其复合年增长率将达7.4%。

莫米松福Mometasone外用製剂能有效缓解各种皮肤疾病引起的红肿、搔痒和其他疼痛。Mometasone是一种皮质类固醇药物，也用于治疗气喘，并且能有效治疗方法各种皮肤过敏和其他过敏性疾病，例如花粉症和过敏性鼻炎。

市场动态

预计气喘在全球的盛行率将持续上升，并在预测期内显着增长。例如，根据世界卫生组织（世卫组织）的数据，2019年有45.5万人死于气喘，全球约有2.62亿人受气喘影响。气喘的误诊率和治疗效果普遍不佳，尤其是在中低收入国家。在最严重的情况下，气喘甚至可能致命。

预计在预测期内，市场相关人员新产品的上市和核准增加将推动全球糠酸Mometasone市场成长。例如，2017年4月，总部位于美国的上市学名药和专科製药公司Amneel Pharmaceuticals LLC推出了Mometasone鼻喷雾该公司首款喷雾剂型药品。 Nasonex是Mometasone莫米鬆的治疗等效物，每次喷雾浓度为50微克。

预计在预测期内，与糠酸Mometasone相关的研发活动的增加将推动市场成长。例如，根据2019年12月发表在医学期刊《Medicine》上的报导，一项在中国进行的研究旨在检验局部应用Mometasone对降低头颈部鳞状细胞癌（HNSCC）患者急性放射性皮肤炎（ARD）的疗效。研究将患者分为两组：试验组和对照组。试验组患者从放射治疗开始至患侧皮肤出现急性放射性皮肤炎（ARD）病变期间，每日一次接受Mometasone治疗；而对照组患者未接受任何治疗。该研究表明，高剂量放射治疗后局部应用Mometasone可以预防急性放射性皮肤炎（ARD）。

本研究的主要特点。

• 本报告对预测期间（2022-2030 年）内全球糠酸Mometasone市场的规模进行了详细分析，以 2021 年为基准年。
• 本报告指出了各个细分市场的潜在商机，并说明了该市场中具有吸引力的投资提案矩阵。
• 此外，本研究还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、区域前景以及主要企业采取的竞争策略的重要见解。
• 本报告根据以下参数分析了全球糠酸Mometasone市场的主要企业：公司概况、财务绩效、产品系列、企业发展区域、分销策略、主要发展和策略以及未来计划。
• 透过利用本报告中提出的见解，企业行销负责人和经营团队可以就未来的产品发布、技术升级、市场扩张和行销策略做出明智的决策。
• 本报告面向该产业的各类相关人员，包括投资者、供应商、製造商、经销商、新参与企业和金融分析师。
• 透过对全球糠酸Mometasone市场进行分析时所使用的各种策略矩阵，相关人员将能够更轻鬆地做出决策。

目录

第一章：研究目标与前提条件

• 研究目标
• 前提
• 简称

第二章 市场概览

• 报告摘要
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map（COM）

第三章：市场动态、监管与趋势分析

• 市场动态
  • 促进因素
  • 阻碍因素
  • 市场机会
• 影响分析
• 波特的分析
• 产业趋势
• 主要亮点
• 流行病学
• 还款状态
• 监理情势
• 产品上市及核准
• 收购与合作趋势

第四章 全球糠酸Mometasone市场：依剂型划分，2026-2033年

• 鼻喷雾
• 奶油
• 软膏
• 吸入器
• 其他的

第五章 全球糠酸Mometasone市场：依适应症划分，2026-2033年

• 发炎性皮肤病
• 气喘
• 过敏性鼻炎
• 其他的

第六章 全球糠酸Mometasone市场：依给药途径划分，2026-2033年

• 鼻喷剂
• 外用
• 口服

第七章 全球糠酸Mometasone市场：依通路划分，2026-2033年

• 医院药房
• 零售药房
• 网路药房
• 其他的

第八章 全球糠酸Mometasone市场：依地区划分，2026-2033年

• 北美洲
  • 我们
  • 加拿大
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • ASEAN
  • 亚太其他地区
• 中东
  • GCC
  • 以色列
  • 其他中东国家
• 非洲
  • 南非
  • 中非
  • 北非

第九章 竞争情势

• 公司简介
  • Cipla
  • Teva Pharmaceuticals
  • Glenmark Pharmaceuticals
  • AdvaCare Pharma
  • Medlab Pharmaceuticals Private Limited
  • Dermocare Laboratories
  • Iva Healthcare Private Limited
  • Unilab Chemicals &Pharmaceuticals Pvt Ltd
  • Organon group of companies
  • Cosette Pharmaceuticals
  • Taro Pharmaceutical Industries Ltd.
  • Hikma Pharmaceuticals.

第十章

• 调查方法
• 关于本公司
• 联繫类型

Mometasone Furoate Market is estimated to be valued at USD 1,582.6 Mn in 2026 and is expected to reach USD 2,608.0 Mn by 2033, growing at a compound annual growth rate (CAGR) of 7.4% from 2026 to 2033.

Mometasone furoate topical is effective at reducing the redness, itching, swelling, and other pain caused by several skin conditions. Mometasone furoate is a corticosteroid drug also used to treat asthma and it is an effective treatment for a variety of skin allergies as well as other allergic conditions like hay fever and allergic rhinitis.

Market Dynamics

Increasing prevalence of asthma worldwide is expected to witness significant growth in forecast period. For instance, according to the World Health Organization (WHO), in 2019, 455 000 individuals died from asthma and an estimated 262 million people were affected by asthma worldwide. Asthma is widely misdiagnosed and poorly managed, particularly in low- and middle-income countries. In most severe cases, asthma can be fatal.

Increasing product launches and approvals by market players are expected to drive growth of the global mometasone furoate market over the forecast period. For instance, in April 2017, Amneal Pharmaceuticals LLC, a U.S.-based, publicly traded generics and specialty pharmaceutical company launched Mometasone furoate nasal spray, the first pharmaceutical product that Amneal Pharmaceuticals LLC had produced in spray form. Nasonex is therapeutic equivalent of mometasone furoate and is offered in 50 mcg/spray strength.

Increasing research and development activities related to mometasone furoate are expected to drive growth of market over the forecast period. For instance, according to an article published in Medicine, medical journal, in December 2019, a study was performed on patients with head and neck squamous cell carcinoma (HNSCC) to check efficacy of local application of mometasone furoate in reducing acute radiation dermatitis (ARD) in China. Patients were divided into two groups, test groups and control groups. The patients in test groups were given mometasone furoate once daily from the start of their radiotherapy until the test side skin acquired ARD lesions, and patients in control groups, were given no treatment at all. The study showed that, mometasone furoate inunction after high dose radiotherapy can prevent acute radiation dermatitis (ARD).

Key features of the study

• This report provides an in-depth analysis of the global mometasone furoate market, market size (US$ Million), and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains an attractive investment proposition matrix for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
• It profiles leading players in the global mometasone furoate market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
• Key companies covered as a part of this study include include Cipla, Teva Pharmaceuticals, Glenmark Pharmaceuticals, AdvaCare Pharma, Medlab Pharmaceuticals Private Limited, Dermocare Laboratories, Iva Healthcare Private Limited, Unilab Chemicals & Pharmaceuticals Pvt Ltd, Organon group of companies, Cosette Pharmaceuticals, Taro Pharmaceutical Industries Ltd., and Hikma Pharmaceuticals
• Insights from this report would allow marketers and the management authorities of the companies to make an informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics.
• The global mometasone furoate market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global mometasone furoate market

Market Segmentation

• Global Mometasone Furoate Market, By Dosage form
  • Nasal Spray
  • Cream
  • Ointment
  • Inhalers
  • Others (Topical Solutions, etc.)
• Global Mometasone Furoate Market, By Indication
  • Inflammatory Skin Disorders
  • Asthma
  • Allergic rhinitis
  • Others (Hay Fever, etc.)
• Global Mometasone Furoate Market, By Route of Administration
  • Nasal Administration
  • Topical
  • Oral
• Global Mometasone Furoate Market, By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Mometasone Furoate Market, By Region
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Global Mometasone Furoate Market, Key Players
  • Cipla
  • Teva Pharmaceuticals
  • Glenmark Pharmaceuticals
  • AdvaCare Pharma
  • Medlab Pharmaceuticals Private Limited
  • Dermocare Laboratories
  • Iva Healthcare Private Limited
  • Unilab Chemicals & Pharmaceuticals Pvt Ltd
  • Organon group of companies
  • Cosette Pharmaceuticals
  • Taro Pharmaceutical Industries Ltd.
  • Hikma Pharmaceuticals.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Overview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Dosage form
  • Market Snippet, By Indication
  • Market Snippet, By Route of Administration
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Porter's Analysis
• Industry Trends
• Key Highlights
• Epidemiology
• Reimbursement Scenario
• Regulatory Scenario
• Product Launch and Approvals
• Acquisition and Collaboration Scenario

4. Global Mometasone Furoate Market, By Dosage Form, 2026-2033 (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026-2033
  • Segment Trends
• Nasal spray
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Cream
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Ointment
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Inhalers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)

5. Global Mometasone Furoate Market, By Indication, 2026-2033 (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026-2033
  • Segment Trends
• Inflammatory skin disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Asthma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Allergic rhinitis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)

6. Global Mometasone Furoate Market, By Route of Administration, 2026-2033 (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026-2033
  • Segment Trends
• Nasal
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Topical
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)

7. Global Mometasone Furoate Market, By Distribution Channel, 2026-2033 (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026-2033
  • Segment Trends
• Hospitals Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)

8. Global Mometasone Furoate Market, By Region, 2026-2033 (USD Mn)

• Introduction
  • Market Share Analysis, By Region, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, For Regions, 2026-2033
  • Regional Trends
• North America
  • Market Size and Forecast, By Dosage Form, 2026-2033 (USD Mn)
  • Market Size and Forecast, By Indication, 2026-2033 (USD Mn)
  • Market Size and Forecast, By Route of Administration, 2026-2033 (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
  • Market Size and Forecast, By Country, 2026-2033 (USD Mn)
    • U.S.
    • Canada
• Latin America
  • Market Size and Forecast, By Dosage Form, 2026-2033 (USD Mn)
  • Market Size and Forecast, By Indication, 2026-2033 (USD Mn)
  • Market Size and Forecast, By Route of Administration, 2026-2033 (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
  • Market Size and Forecast, By Country, 2026-2033 (USD Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Market Size and Forecast, By Dosage Form, 2026-2033 (USD Mn)
  • Market Size and Forecast, By Indication, 2026-2033 (USD Mn)
  • Market Size and Forecast, By Route of Administration, 2026-2033 (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
  • Market Size and Forecast, By Country, 2026-2033 (USD Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Market Size and Forecast, By Dosage Form, 2026-2033 (USD Mn)
  • Market Size and Forecast, By Indication, 2026-2033 (USD Mn)
  • Market Size and Forecast, By Route of Administration, 2026-2033 (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
  • Market Size and Forecast, By Country, 2026-2033 (USD Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Market Size and Forecast, By Dosage Form, 2026-2033 (USD Mn)
  • Market Size and Forecast, By Indication, 2026-2033 (USD Mn)
  • Market Size and Forecast, By Route of Administration, 2026-2033 (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
  • Market Size and Forecast, By Country, 2026-2033 (USD Mn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Market Size and Forecast, By Dosage Form, 2026-2033 (USD Mn)
  • Market Size and Forecast, By Indication, 2026-2033 (USD Mn)
  • Market Size and Forecast, By Route of Administration, 2026-2033 (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
  • Market Size and Forecast, By Country/Region, 2026-2033 (USD Mn)
    • South Africa
    • Central Africa
    • North Africa

9. Competitive Landscape

• Company Profiles
  • Cipla
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
  • Teva Pharmaceuticals
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
  • Glenmark Pharmaceuticals
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
  • AdvaCare Pharma
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
  • Medlab Pharmaceuticals Private Limited
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
  • Dermocare Laboratories
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
  • Iva Healthcare Private Limited
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
  • Unilab Chemicals & Pharmaceuticals Pvt Ltd
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
  • Organon group of companies
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
  • Cosette Pharmaceuticals
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
  • Taro Pharmaceutical Industries Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
  • Hikma Pharmaceuticals.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Analyst Views

10. Section

• Research Methodology
• About us
• Contact